Although findings from a large retrospective study supports these positive effects of taking a GLP-1, it’s unclear whether ...

Novartis' blockbuster heart treatment Entresto saw sales growth stall in the third quarter of the year, dragging the Swiss ...

Semaglutide, the active ingredient in Wegovy and Ozempic, lowers major cardiac event risk, regardless of how much weight a ...

The use of sacubitril/valsartan appears feasible and safe in recipients of left ventricular assist devices, reducing the need ...

Regardless of how much weight you lose, GLP-1 drugs like Wegovy and Ozempic could decrease major adverse cardiovascular ...

In combination, two commonly used heart drugs reverse fat accumulation in the liver, a study in animals has shown.

A new analysis finds that the heart-protecting benefits of semaglutide are largely independent of its weight loss effects.

An analysis found that a shrinking waist size was responsible for only around a third of the cardiovascular benefits in ...

Vadodara: Alembic Pharmaceuticals Limited has announced that the company has received final approval from the US Food & Drug ...

The Drugs Control Administration, Telangana, has found gyms and fitness centres illegally selling steroids and stimulants ...

Novartis has started to feel the squeeze from generics to its top-selling drug, heart therapy Entresto. | Novartis has ...

Michael Gotthardt at the Max Delbrück Center and collaborators are developing a drug to treat a common type of heart failure ...